Larimar Therapeutics (LRMR) Depreciation & Amortization (CF) (2013 - 2025)
Larimar Therapeutics (LRMR) posted Depreciation & Amortization (CF) of $87000.0 for Q4 2025, down 1.14% on a QoQ basis from $88000.0 in Q3 2025, and up 12.99% year-over-year from $77000.0 in Q4 2024.
Larimar Therapeutics (LRMR) Depreciation & Amortization (CF) (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $87000.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 12.99% year-over-year to $87000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $350000.0 (up 10.06% YoY) and the FY2025 annual result came in at $350000.0, up 10.06% from the prior year.
- Depreciation & Amortization (CF) was $87000.0 for Q4 2025 at Larimar Therapeutics, down from $88000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $100000.0 in Q1 2021 and bottomed at $50000.0 in Q2 2021.
- A 5-year average of $81750.0 and a median of $81000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Peak annual rise in Depreciation & Amortization (CF) reached 334.78% in 2021, while the deepest fall reached 50.0% in 2021.
- Larimar Therapeutics' Depreciation & Amortization (CF) stood at $88000.0 in 2021, then declined by 11.36% to $78000.0 in 2022, then grew by 3.85% to $81000.0 in 2023, then retreated by 4.94% to $77000.0 in 2024, then grew by 12.99% to $87000.0 in 2025.
- Business Quant data shows LRMR's Depreciation & Amortization (CF) at $87000.0 in Q4 2025, $88000.0 in Q3 2025, and $87000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | 87,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 76,000.00 |
| Sep 30, 2023 | 76,000.00 |